TABLE 1.
Characteristics | Compensated NAFLD cirrhosis (n = 16) | Decompensated NAFLD cirrhosis (n = 9) | p-value |
---|---|---|---|
Demographics and co-morbidities | |||
Age, years | 63 (11) | 68 (8) | 0.44 |
Female (%) | 82 | 89 | 1.0 |
Hispanic (%) | 50 | 67 | 0.68 |
Caucasian (%) | 38 | 22 | 0.66 |
Type II diabetes (%) | 82 | 89 | 1.0 |
Body mass index (kg/m2) | 35.3 (11.4) | 29.9 (6.9) | 0.22 |
Tobacco use (%) | 0 | 0 | 1.0 |
Laboratory results | |||
AST (IU/L) | 42 (19) | 58 (28) | 0.17 |
ALT (IU/L) | 45 (36) | 48 (42) | 0.46 |
Total bilirubin (mg/dl) | 0.71 (0.45) | 5.1 (11.27) | 0.01 |
Platelet count (109/L) | 183 (63) | 97 (61) | 0.01 |
Albumin (g/dl) | 4.3 (0.3) | 3.6 (0.8) | 0.01 |
INR | 1.1 (0.1) | 1.4 (0.5) | <0.01 |
Fasting insulin (mIU/L) | 39.1 (30.8) | 40.6 (24.6) | 0.89 |
Glycated haemoglobin (%) | 7.5 (1.7) | 6.3 (2.1) | 0.07 |
Triglycerides (mg/dl) | 131 (62) | 179 (213) | 0.83 |
Low-density lipoprotein (mg/dl) | 83 (33) | 71 (34) | 0.38 |
High-density lipoprotein (mg/dl) | 52 (15) | 42 (21) | 0.24 |
Medication use, n (%) | |||
Proton pump inhibitor | 5 (31%) | 1 (11%) | 0.37 |
Lactulose | 0 (0%) | 6 (67%) | <0.01 |
Rifaximin | 0 (0%) | 4 (44%) | <0.01 |
Metformin | 10 (63%) | 3 (33%) | 0.23 |
Antibiotic prophylaxis for SBP | – | 0 (0%) | – |
Liver disease severity | |||
MELD score | 7.2(1.2) | 15.6 (8.9) | <0.01 |
Ascites, n (%) | 0 (0%) | 3 (33.33%) | 0.04 |
Hepatic encephalopathy, n (%) | 0 (0%) | 5 (55.56%) | <0.01 |
Variceal bleeding, n (%) | 0 (0%) | 2 (22.22%) | 0.12 |
Prior TIPS, n (%) | 0 (0%) | 1 (11.11%) | 0.36 |
Note: Mean (standard deviation).
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR; international normalised ratio; SBP, spontaneous bacterial peritonitis; MELD, Model For End Stage Liver Disease; NAFLD, Non-alcoholic fatty liver disease; TIPS, transjugular intrahepatic portosystemic shunt.